Sun Pharmaceutical Advanced Research Company | Sustainability & Chart

INE232I01014

Basic information on Sun Pharmaceutical Advanced Research Company

Location: India

Industry: Manufacturing

Website

Impact Score

Description Sun Pharmaceutical Advanced Research Company

Sun Pharmaceutical Advanced Research Company Limited is an India-based pharmaceutical research company focused on drug discovery, development, and drug delivery systems. It works on specialty and innovative products across therapeutic areas and may out-license or partner selected programs.

Sun Pharmaceutical Advanced Research Company Sustainability Performance

Climate

61%

Renewable Energy

Sun Pharmaceutical Advanced Research Company obtains 52,6% of its energy from renewable energies. Target value per method: min. 100%

Greenhouse Gas Emissions

Sun Pharmaceutical Advanced Research Company emits 1,4 times its CO₂ budget of 228,433 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Supply Chain

Taking into account the entire supply chain, Sun Pharmaceutical Advanced Research Company emits 3,8 times its CO₂ budget of 226,593 tons of CO₂ equivalent. Target value per method: max. 100% of CO₂ budget

Recycling and Recovery of Waste

Sun Pharmaceutical Advanced Research Company recycles 72,3% of its waste. Target value per method: min. 75%

Society

51%

Union Formation and Collective Bargaining Power

Sun Pharmaceutical Advanced Research Company issues 0% collective agreements. Target value per method: min. 80%

CEO Pay Ratio

CEO Dilip Shanghvi earns 111 times the median salary of employees. Target value per method: max. 30 times

Employee Turnover Rate

Sun Pharmaceutical Advanced Research Company has an employee turnover rate of 13,2%. Target value per method: max. 10%

Harassment and Discrimination at the Workplace

Sun Pharmaceutical Advanced Research Company meets 4 quality criteria for handling harassment and discrimination at the workplace. Target value per method: 4 quality criteria

Gender

57%

Women on Board

Sun Pharmaceutical Advanced Research Company has 30% women across its top leadership and supervisory bodies. Target value per method: min. 40%

Gender Pay Gap

No data available for Sun Pharmaceutical Advanced Research Company. Target value per method: max. 3%

Women in Management

Sun Pharmaceutical Advanced Research Company employs 21,8% female managers. Target value per method: min. 40%

Glass Ceiling

The proportion of women in senior management at Sun Pharmaceutical Advanced Research Company is 388,2% of the proportion of women in the overall workforce. Target value per method: min. 90%

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

Renewable Energy

Greenhouse Gas Emissions

Supply Chain

Waste Recycling

Sustainable [100]

Almost sustainable [67-99]

Moderate [34-66]

Not sustainable [0-33]

No data

We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.

Compare Sun Pharmaceutical Advanced Research Company with ...

Sun Pharmaceutical Advanced Research Company

?

Impact Score

Climate

Society

Gender

61%

51%

57%

Sun Pharmaceutical Advanced Research Company

?

Impact Score

Climate

Society

Gender

Sources of sustainability performance

Metric	Value	Unit	Year	PDF Name	PDF Page
CEO Pay Ratio
CEO name	Dilip Shanghvi		2025	Sun-Pharma_AR-2025-26.pdf	61
CEO-to-median-salary-ratio	111,1	Ratio	2025	Sun-Pharma_AR-2025-26.pdf	61
Employee Turnover Rate
Employee turnover	13,18	%	2025	Sun-Pharma_AR-2025-26.pdf	108
Glass Ceiling
Women on executive board	1	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Women in workforce	12,88	%	2025	Sun-Pharma_AR-2025-26.pdf	108
Executive board size	2	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Greenhouse Gas Emissions
Scope 1 emissions	63 388	tCO2e	2025	Sun-Pharma_AR-2025-26.pdf	134
Number of employees	47 000	people	2025	Sun-Pharma_AR-2025-26.pdf	11
Scope 2 emissions, location based	261 170	tCO2	2025	Sun-Pharma_AR-2025-26.pdf	134
Harassment and Discrimination at the Workplace
Retaliation safeguards	Yes		2025	Sun-Pharma_AR-2025-26.pdf	130
Incident notification mechanism	Yes		2025	Sun-Pharma_Global-Code-of-Conduct-1-April-2025.pdf	5
Anti-discrimination policy	Yes		2025	Sun-Pharma_Global-Code-of-Conduct-1-April-2025.pdf	8
Confidentiality mechanisms	Yes		2025	Sun-Pharma_AR-2025-26.pdf	130
Renewable Energy
Total renewable energy consumption	52,55	%	2025	Sun-Pharma_AR-2025-26.pdf	132
Supply Chain
Scope 3 emissions	379 788	tCO2e	2024	Sun-Pharma-Sustanability-Report-FY-2023-24.pdf	70
Scope 2 emissions, location based	323 237	tCO2e	2024	Sun-Pharma-Sustanability-Report-FY-2023-24.pdf	69
Scope 1 emissions	156 242	tCO2e	2024	SPIL-Annual-Report-2024-25.pdf	122
Number of employees	43 000	people	2024	SPIL-Annual-Report-2024-25.pdf	11
Union Formation and Collective Bargaining Power
Collective bargaining agreements coverage	0	%	2025	Sun-Pharma_AR-2025-26.pdf	123
Recycling and Recovery of Waste
Waste recycled	34 497	metric tonnes	2025	Sun-Pharma_AR-2025-26.pdf	135
Total waste generation	47 737	metric tonnes	2025	Sun-Pharma_AR-2025-26.pdf	135
Women on Board
Executive board size	2	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Women on executive board	1	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Women on supervisory board	2	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Supervisory board size	8	people	2025	Sun-Pharma_AR-2025-26.pdf	108
Women in Management
Women in management	252	Employees	2024	Sun-Pharma-Sustanability-Report-FY-2023-24.pdf	87
People in management	1 158	Employees	2024	Sun-Pharma-Sustanability-Report-FY-2023-24.pdf	87

Note: The PDF pages given here refer to the page in the PDF document, which is not necessarily the one found in the footer of the page. For example, page 10 is the 10th page in the document, even if it is labeled as page 8.

Find more sustainable companies

Home Find Companies & ETFs Learn to invest Academy Glossary Our Method

Imprint Privacy Policy GTC FAQContact Us

© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev